Johnson & Johnson acquires Ambrx Biopharma for approximately $2bn
March 11, 2024Business Services ADCs, Ambrx Biopharma, J&J, Johnson & Johnson, Oncology, acquisition
Johnson & Johnson (J&J) has announced that it has successfully completed its acquisition of Ambrx Biopharma in an all-cash merger …
Aspire Pharma acquires Cenoté Pharma
March 11, 2024Business Services Aspire Pharma, Cenoté Pharma, Pharmacy, acquisition
Aspire Pharma has announced that it has successfully acquired Cenoté Pharma as part of its plan to supplement its growth …
BeiGene’s Brukinsa gains FDA accelerated approval for follicular lymphoma treatment
March 8, 2024Medical Communications BeiGene, Brukinsa, FDA, Oncology, follicular lymphoma
BeiGene has announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa (zanubrutinib) for the …
Roche shares data on novel solution for continuous glucose monitoring
March 8, 2024Research and Development Diabetes, Medical device, Roche, continuous glucose monitoring, diabetes
Roche has shared the latest data on its novel solution for continuous glucose monitoring (CGM), including a CGM sensor and …
GSK shares results from phase 3 trial for Blenrep for treatment of multiple myeloma
March 7, 2024Research and Development Blenrep, GSK, Oncology, clinical trial, multiple myeloma
GSK has announced positive results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial which assesses Blenrep (belantamab …
Gilead and Merck share data from phase 2 trial of HIV treatment
March 7, 2024Research and Development Gilead Sciences, HIV, HIV/AIDS, Merck, clinical trials
Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced results from the phase 2 …
Measles: the UK’s next epidemic?
March 6, 2024MMR, measles, vaccines
Recently, the UK has seen a rapid increase in the number of cases of measles, along with a drop in …
FDA approves Sandoz’s denosumab biosimilars
March 6, 2024Medical Communications FDA, Jubbonti, Musculo-skeletal disorder, Sandoz, Wyost, denosumab
Sandoz has announced that the US Food and Drug Administration (FDA) has approved Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), which are …
Regenxbio announces initial efficacy data from phase 1/2 AFFINITY DUCHENNE trial
March 6, 2024Research and Development Duchenne Muscular Dystrophy, Musculo-skeletal disorder, Regenxbio, clinical trial
Regenxbio has announced additional interim safety data from its phase 1/2 AFFINITY DUCHENNE trial of RGX-202 in patients with Duchenne …
GSK’s Jemperli recommended by NICE for endometrial cancer treatment
March 5, 2024Medical Communications GSK, Jemperli, NICE, Oncology, endometrial cancer
GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of Jemperli (dostarlimab) …
Novartis shares new data for Zolgensma in children with SMA
March 5, 2024Musculo-skeletal disorder, Novartis, Zolgensma, sma, spinal muscular atrophy
Novartis has announced new data to continue the support of the clinical benefits of Zolgensma (onasmenogene abeparvovec), for the treatment …
FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment
March 4, 2024Medical Communications FDA, Johnson & Johnson, NSCLC, Oncology, Rybrevant
Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved Rybrevant (amibantamab-vmjw) following a priority …
EMA validates two applications for datopotamab deruxtecan for cancer treatments
March 4, 2024Medical Communications CHMP, Daiichi Sankyo, EMA, Oncology, datopotamab deruxtecan
AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications (MAAs) for AstraZeneca and Daiichi …
Cardiff Oncology doses first patient in colorectal cancer trial
March 1, 2024Research and Development Cardiff Oncology, Oncology, clinical trial, colorectal cancer
Cardiff Oncology has announced that it has dosed the first patient in its randomised first-line phase 2 trial, CRDF-004, for …
Viracta Therapeutics completes enrolment for T-cell lymphoma cohort in NAVAL-1 trial
March 1, 2024Medical Communications Oncology, Viracta Therapeutics, lymphoma
Viracta Therapeutics has announced that it has completed stage 2 enrolment into the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) …
AstraZeneca’s Voydeya recommended for approval in EU by CHMP
February 29, 2024Medical Communications AstraZeneca, CHMP, EMA, Haematology, Voydeya
AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) by the Committee …
Spero Therapeutics’ bacterial infection treatment gains FDA IND clearance
February 29, 2024Medical Communications FDA, Infections and infestations, Spero Therapeutics, bacterial infections, investigational new drug
Spero Therapeutics has announced that it has gained US Food and Drug Administration (FDA) clearance for the investigational new drug …
Viatris and Idorsia enter research and development collaboration
February 28, 2024Research and Development Idorsia, Pharmacy, Viatris, acute myocardial infarction, systemic lupus erythematosus
Viatris and Idorsia have announced that they have entered into agreements for a significant global research and development collaboration. Under …
Amneal and Zambon Biotech enter agreement for Parkinson’s treatment
February 28, 2024Research and Development Amneal pharmaceuticals, Neurology, Parkinson's disease, Zambon Biotech, licensing agreement
Amneal Pharmaceuticals has announced that it has entered into an exclusive licensing agreement with Zambon Biotech for IPX204 in the …
GSK shares positive results from phase 3 trial for gonorrhoea treatment
February 27, 2024Research and Development GSK, Infections and infestations, antibiotic, clinical trial, gonorrhoea
GSK has announced positive headline results from its phase 3 EAGLE-1 trial for gepotidacin, its potential first-in-class oral antibiotic with …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
